Who are Fluphenamic Acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Phenylbutazon, Aspirin, Azophen, Benzeneformic Acid, Acetanil, Indom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flufenamic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fluphenamic Acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluphenamic Acid (FLUFENAMIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: flufenamic acid. Area: Pain.

marketed flufenamic acid Nicotinate phosphoribosyltransferase Pain Small molecule Live · refreshed every 30 min

Target snapshot

Fluphenamic Acid (FLUFENAMIC ACID).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluphenamic Acid TARGET	FLUFENAMIC ACID		marketed	flufenamic acid	Nicotinate phosphoribosyltransferase
Phenylbutazon	PHENYLBUTAZONE	Novartis	marketed	phenylbutazone	Nicotinate phosphoribosyltransferase, Prostacyclin synthase, Cytochrome P450 2C9	1980-01-01
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Azophen	phenazone		marketed	phenazone	Nicotinate phosphoribosyltransferase
Benzeneformic Acid	benzoic acid		marketed	Nitrogen Binding Agent [EPC]	Nicotinate phosphoribosyltransferase
Acetanil	ACETANILIDE		marketed	acetanilide	Nicotinate phosphoribosyltransferase
Indom	Indom	University of Trieste	marketed		Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (flufenamic acid class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluphenamic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/flufenamic-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing